Congrats leaders!

I'm hiding between the sheeps for now.

out of curiosity, could i put in a trade today, trading cash for some stock, as an august trade?

Agreed. Great call on PSIX Mr. KiK!

Great story jtomm. I always remember Lentinman fondly.

What other brokerage are you considering?

fwiw, Roy Sebag at Goldmoney (XAU.TO) has been buying for the past 6 weeks consistently ...
https://stockhouse.com/companies/insiders?symbol=t.xau

Anyone follow Lantronix (LTRX)? I just looked at it for the 1st time. Any thoughts?

Schwab different question ... On TDA, when looking at my positions, I could hover over a symbol, and it would give me things to look at with that stock, one of which was level two chart. Does Schwab have something similar?

Schwab ...

the only thing I noticed recently is I put in a limit sell order 1 cent below the bid, and even though the bid did not change, it still executed at the lower price.

Nsom is on fire ...

DD picks (missed one)

VNDA - has had two buyout bids for about $8, board has turned them down, so the stock just starts drifting down again, i'm betting on another bid

my picks DD

NEM - gold stock, large producer, decent divvy
FTCO - gold stock, 11% divvy, strong balance sheet, down because delay in permit approval, unknown when they will be approved
GILT - my weakest pick, just threw it in there
CSPI - did it for tomorrow. but seriously cyber crime a growing area, should continue to benefit
APT - just a play on viral disease outbreaks basically
BCRX - used to own a lot, fallen a lot, seems to have bottomed, potential spikes on partnership/new drug success, etc ...
ANVS - developing drug for alzheimers/parkinsons, has fallen a lot, big potential for spikes as they get closer to final results
IFA.TO - makes applications for textiles (anti fungal, bacterial, sweating, wicking, etc... seems to have bottomed, revs growing, couple possible catalysts this year.
MBX.TO - this is more of a five year big bet for me, but it's my largest position, so threw it in here. Possible partnerships, growing sales, big catalyst in a few years, should have big royalty stream

congrats value, maybe I'll make it up that way someday.

PSIX - dang, that is awesome. Congrats and a great heads-up along the way here.

I got timed out, now can't sign back in again

logged in on 3rd try (thought pw was incorrect, but it wasn't).

nelson, two very cool things, I would recommend trying to do both. Let us know how they go.

Sskillz1, sorry, was out of town, and just saw your messages. I apologize for any issues.

$4.95 at tda? Man, I've been paying $6.95 over the years. I guess I should have known and spoken up!

Congrats researcher59! And I appreciate your posts over the years (decades). Thanks to Sskillz again and again.

This release from November talks about their expansion to increase warehouse space ...
https://finance.yahoo.com/news/ifabric-corp-announces-expansion-move-113000221.html

Then this buy of $20K on 2/5/24 by board member gives me hope there will be some positive momentum moving forward ...
https://ceo.ca/api/sedi/?symbol=IFA&amount=&transaction=buy-sell-public&insider=Groome%2C+Cameron+Lionel

Jerash (JRSH) quarterly earnings highlights trouble companies shipping in the Red Sea are facing. I don't own any of this, but makes me think about some other companies that may be affected ...
https://finance.yahoo.com/news/jerash-holdings-reports-fiscal-2024-130000205.html

gilead re:job numbers , Mish tries to explain this as well ...

https://mishtalk.com/economics/ignore-the-amazing-headline-job-numbers-note-the-revisions/

FTCO, just got home and see that. wow. will probably add some more shortly

hweb re:FTCO, this from respected poster on yahoo ...

Hanz
3 hours ago
Gold Panda is back at Seeking Alpha and claims Isabella Pearl is running out of high-grade ore and financial results will deteriorate over 2024. The author looks at Q4 production as template for the future and doesn’t seem to realize it is missing the distinction between mining, inventory and production.

End of Q3 calculations were gold left to be mined 10,092 oz after 81% recovery, inventory 57,648 oz, total remaining production 67,740 oz. In one way the author is correct, there were only 10,092 oz to be mined from the ground left, they are running out. Author estimates 7000 oz of still to be mined (proven and probable reserves), take 81% of that is 5670 oz, not that far off from 10,092 oz. However, FTCO has much more gold than P&P, it was already mined and is waiting (inventory) for sale (production). Don’t know how much was mined in Q4 yet, so can’t calculate the inventory size. However, worse case inventory is 51,945 oz for sales potential at beginning of 2024, it assumes nothing mined in Q4.

The author thinks mining might have to shut down in the coming months. Close to correct on one aspect, IP mining from the ground is already shut down waiting for permits. Year 2023 was difficult for FTCO staff, extra work and extra disruption, speculating December was a skeleton crew. Production will continue out of inventory at a really low production cost due to no mining from the ground and processing already crushed on the heap inventory. When IP receives the permit
the production cost will go up.

CSPI might benefit from something like this ...
https://abcnews.go.com/Politics/chinas-hackers-preparing-wreak-havoc-cause-real-world/story?id=106815323

FTCO, yeah, I saw that. I have not picked up on things being so bad, but they have been delayed getting permits. If today's pessimism persists, I would expect the company to clarify their plans going forward to counter that article.

currently FTCO at 5.80 yielding 8%

Good stuff Bobwins. Thank you.

looks like a good day for SASI. Good luck Rocketeer!

TD - They recently told me a weekend in May

In addition to Kinlytic, Microbix has three other product lines. Antigens, which are used in PCR diagnostic testing. This business is historically about $12M/year. It slowed during the pandemic, but is now nearly back to historical levels, and at higher gross margins, due to improvements in moving from rolling bottles to bioreactors. There is also opportunity for expansion in to the China market.

Second product is VTM (viral transport medium), the vials (with solution) that are used to transport samples taken for respiratory diseases (swab your nose for covid/etc ...). This was about $5M/year for 2021/2022, but has dried up. It may return, or they will use that manufacturing space for their other products.
The third product is their quality assurance products (QAP's), that are used to validate that diagnostic test equipment is working correctly. This business is growing, and is expected to be the main driver of growth. They are partnering with diagnostic testing companies to include with their testing products, as well as providing to labs around the world.
Last year, the company did about $18M in sales, are targeting roughly $30M for 2024, and have geared up their facilities to do $100M in the next 3 to 5 years. This company is not well known, but should be. They are a hidden gem, and this is an excellent time to get onboard. They have a great balance sheet, will not need any financing, and they are buying back stock (to retire) through their NCIB program.

Currently this market is a monopoly for TPA by Genetech. The catheter clearance market in the U.S. is estimated currently at $350M+. It will likely take 3 years to bring Kinlytic to market. Estimated fair value of Kinlytic is roughly $95M. Current market cap on Microbix is $38M. This is an FDA approved drug. They have to find a manufacturer, then show that the newly manufactured drug is similar/equivalent to the previous product. Sequel Pharma will be paying the estimated $35M for this process. Microbix/Sequel have been in discussions with the FDA about how to proceed, and based on these discussions, Sequel has made the commitment to fully find this and proceed.

Kinlytic continued ...

Back in May, Microbix partnered with Sequel Pharma to bring back Kinlytic to the market. So far, they have received $4M in payments, will receive another million upon filing the supplemental BLA, can earn $30M with sales milestone payments. ALSO, they will earn double digit royalties on sales, which are estimated at $15 to $25M per year once fully ramped up.
This is based on the catheter clearance market in the U.S. only. Eventually that may expand to Europe, Canada, and other continents/countries. It may also expand to other indications (thrombolytic therapy/embolism). And Microbix will continue to get royalties.

Kinlytic:

Kinlytic is a thrombolytic injectable drug, commonly known as a clot buster. It has been used to treat over 4 million patients with life-threatening pulmonary embolism and clot obstructed intravenous catheters. Microbix owns the rights to the drug, which is approved in the United States and Canada for treatment of life threatening blockages to blood flow in the lungs (pulmonary embolism) and to remove blood clots from intravenous catheters, essential to patient treatment for drug administration and nutrition.

The active ingredient in Kinlytic is urokinase, a serine protease found normally in the human body. Kinlytic is the low molecular weight form of urokinase (LMW-UK) produced through a biotechnology based cell culture process. Urokinase is effective in clearing clot related blockages via its protein cleaving enzymatic action leading to breakdown of fibrin, a major structural component of blood clots. Physicians have used urokinase to treat over 4 million patients in North America given its well established reputation for efficacy and safety. Kinlytic is the only LMW-UK approved worldwide for patient treatment.
Microbix developed its urokinase manufacturing experience by building on its knowledge of cell culture and purification used in its diagnostic products manufacturing processes. Originally, Microbix planned to compete with Abbott Laboratories by manufacturing a biosimilar drug. Subsequently the Company acquired the Abbokinase assets, which had been rebranded as Kinlytic, including the “NDA approvals” in both the US and Canada. With the acquisition, Microbix became the sole owner of regulatory approvals and know-how for the production of low molecular weight urokinase.

Congratulations Digitech !! Impressive numbers.

Also, thanks to SSKiILLZ (again) for running this and all contests.

Microbix (MBX.TO - my largest holding (for a few years now), may finally get some traction. If you're bored on this Friday, they have an investor update at 10, that might be interesting. Most of it will center on their agreement with Sequel Pharma to commercialize their urokinase product. Initially it will be for catheter clearance in the U.S. only, but wil eventually probably expand to ither geographies and other indications.
This product used to be owned by Abbott 20 years ago, and due to some manufacturing (then restructuring issues), they sold it. At the moment, TPA is a monopoly owned by Genentech. That should change in the next few years, and Microbix would start collecting substantial royalties . Not a short term flip but a attractive multi year play.

good one Nelson.

FTCO, I agree. Very conservative with their money. The CEO "sounds" like he expects County Line, and then Golden Mile to go into production, and they are "optimistic" that they might add some more reserves at Isabella Pearl. But of course, no guarantees. I've been buying more below $6.

Mr. Sheep in the top five. Not too shabby!